Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis With Results to Be Presented at the American Heart Association Scientific Sessions 2024

newsfileSep 10 07:27 ET

Cardiol Therapeutics Inc.: Financial Update

TipRanksAug 12 17:27 ET

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

newsfileJun 27 12:29 ET

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 P.m. EDT

newsfileJun 25 07:27 ET

Cardiol Therapeutics Releases Phase II Data Showing CardiolRx Reduces Pericarditis Pain and Inflammation | TSX:CRDL, NASDAQ:CRDL

Proactive InvestorsJun 13 08:08 ET

Cardiol Therapeutics Announces Positive Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

newsfileJun 13 07:58 ET